


**PRODUCT: GSK-503****ALTERNATE NAME:** N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide**CATALOG #:** 9538-5, 25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C<sub>31</sub>H<sub>38</sub>N<sub>6</sub>O<sub>2</sub>**MOLECULAR WEIGHT:** 526.67**CAS NUMBER:** 1346572-63-1**APPEARANCE:** Off-white solid**SOLUBILITY:** DMSO (>5 mg/ml)**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20°C. Protect from air and light**DESCRIPTION:** GSK-503 is a potent EZH2 inhibitor with potential anticancer activity. Increased activity of the epigenetic modifier EZH2 has been associated with different cancers. In a melanoma mouse model, conditional Ezh2 ablation as much as treatment with the preclinical EZH2 inhibitor GSK503 stabilizes the disease through inhibition of growth and virtually abolishes metastases formation without affecting normal melanocyte biology.**REFERENCES:** Zingg, D., et al. (2015). *Nat Commun.* **6**, 6051**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

A-366 (Cat. No. 2859-1, 5)

AMI-1 (Cat. No. 1943-5, 25)

Aza-2'-deoxycytidine (Cat. No. 1754-10, 50)

5- BIX01294 (Cat. No. 1678-5, 25)

Bromodomain Inhibitor, (+)-JQ1 (Cat. No. 2070-1, 5)

BRD4770 (Cat. No. 9525-5, 25)

EZSolution™ (+)-JQ1 (Cat. No. 2091-1)

3-Deazaneplanocin (Cat. No. 2060-250, 1000)

2'-Deoxy-5-fluorocytidine (Cat. No. 2387-50, 250)

EPZ-015666 (Cat. No. 9510-1,5)

Lomeguatrib (Cat. No. 2224-5, 25)

Nanaomycin A (Cat. No. 2790-5, 25)

RG108 (Cat. No. 1679-10, 30)

SGI-1027 (Cat. No. 2726-5, 25)

UNC0638 (Cat. No. 1933-1, 5)

UNC0642 (Cat. No. 2862-5, 25)

Zebularine (Cat. No. 2225-1, 5)

**USAGE:** **FOR RESEARCH CH USE ONLY! Not to be used in humans**